Orphan Australia

Orphan Australia was a specialized pharmaceutical company based in Australia that focused on the identification, registration, and commercialization of "orphan drugs" for rare diseases and life-threatening conditions. Established in 1994, the company played a critical role in providing access to niche therapies that larger pharmaceutical firms often overlooked due to small patient populations. Its business model involved partnering with international biotechnology and research organizations to bring innovative treatments to the Australian and New Zealand markets. In 2008, Orphan Australia was acquired by Sigma Pharmaceuticals for AUD 60 million to bolster its specialty products division. Following Aspen Pharmacare's acquisition of Sigma's pharmaceutical business in 2010, the Orphan Australia portfolio was integrated into Aspen's global operations.